NCT01932125已完成4 期
An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 13
- 主要终点
- Safety: Incidence of adverse events
研究概览
简要总结
This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Prescribed to receive bevacizumab or already ongoing on treatment with bevacizumab for advanced/metastatic ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) according to routine clinical practice
排除标准
- •Not eligible for treatment with bevacizumab according to the local prescribing information
研究组 & 干预措施
Cohort
Experimental
干预措施: Bevacizumab (Drug)
结局指标
主要结局
Safety: Incidence of adverse events
时间窗: up to approximately 1.5 years
次要结局
- Progression-free survival(up to approximately 1.5 years)
- Overall survival(up to approximately 1.5 years)
- Overall response rate (complete response + partial response)(up to approximately 1.5 years)
- Clinical benefit rate (complete response + partial response + stable disease)(up to approximately 1.5 years)
研究者
研究点 (13)
Loading locations...
相似试验
已完成
不适用
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)Colorectal CancerNCT01506167Hoffmann-La Roche719
已完成
不适用
An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)Renal Cell CancerNCT01392729Hoffmann-La Roche40
已完成
不适用
An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell CarcinomaRenal Cell CancerNCT01351571Hoffmann-La Roche5
已完成
不适用
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)Ovarian CancerNCT01863693Hoffmann-La Roche300
已完成
不适用
AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast CancerBreast CancerNCT01777932Hoffmann-La Roche220